22:55 , Oct 11, 2018 |  BC Week In Review  |  Financial News

JHL raises financing at $750M valuation

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised an undisclosed amount in a private financing at a valuation of $750 million. Participating in the financing were Sanofi (Euronext:SAN; NYSE:SNY) and other undisclosed investors, according to...
18:22 , Oct 5, 2018 |  BC Extra  |  Financial News

JHL raises financing at $750M valuation

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised an undisclosed amount in a private financing at a valuation of $750 million. Participating in the financing were Sanofi (Euronext:SAN; NYSE:SNY) and other undisclosed investors, according to...
07:00 , Aug 24, 2015 |  BioCentury  |  Finance

Makings of a bellwether

Taiwan's JHL Biotech Inc. has started the public listing process and while it's unclear what valuation will be ascribed to the biosimilar developer and biologics manufacturer, JHL's track record of raising money suggests the numbers...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
08:00 , Jan 15, 2007 |  BioCentury  |  Finance

Ebb & Flow

Wednesday's luncheon at the JPMorgan 25th Annual Healthcare Conference took a different tack on a panel discussion. Instead of the firm's analysts answering questions, the 1,000-member audience was asked to respond to a battery of...
02:01 , Jan 9, 2007 |  BC Extra  |  Financial News

Proprius raises $11 million

Proprius (San Diego, Calif.) raised $11 million in a series A round led by Atlas Venture. New investors Forward Ventures and CDIB BioScience Venture Management joined existing investors Fog City Fund and Windamere in the...
08:00 , Feb 27, 2006 |  BioCentury  |  Finance

Ebb & Flow

Amgen (AMGN) is no stranger to stock buybacks, but for only the second time, the bellwether has dipped into the debt market to supplement its share repurchases. Investors are on board with the move, which...
07:00 , Jul 25, 2005 |  BioCentury  |  Strategy

Pipeline to East Asia

HenKan Pharmaceutical Co. says its first deal, with CombinatoRx Inc. , is part of its strategy to act as a gatekeeper to China, Taiwan and South Korea. The company hopes to in-license more products from...
08:00 , Jan 7, 2002 |  BC Extra  |  Financial News

Taiwan venture fund closes

CDIB BioScience Venture Management raised NT$2.6 billion ($75.5 million) for CDIB BioScience Ventures I, a life science venture fund spinoff from the China Development Industrial Bank (CDIB). Tai-Sen Soong, serves as president of the new...
08:00 , Jan 7, 2002 |  BioCentury  |  Finance

Ebb & Flow

InterMune (ITMN) lost $207 million of its value last week as investors dumped shares on rumors that the company was seeing a larger-than-expected dropout rate for its Phase III trial of Actimmune interferon gamma-1b in...